— Regeneron Pharmaceuticals (NASDAQ: REGN) reported Q4 2019 earnings of $7.50 per share, vs. $6.92 expected.
— Revenues grew 13% to $2.17 billion, vs. $2.11 billion expected.
— Net product sales were $1.28 billion.
— EYLEA net product sales in the US were $1.22 billion.
— Sanofi and Bayer collaboration revenues were $748 million.
— R&D expenses totaled $683 million.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
IPO News: Monte Rosa Therapeutics will go public this week, here are a few things to know
Biotechnology company Monte Rosa Therapeutics is slated to go public this week. In a pandemic-ridden world, this industry is expanding at a healthy pace. The global biotechnology market is estimated
IPO News: What to look for when Elevation Oncology makes its Wall Street debut
The healthcare sector is going through a phase of consolidation, creating fresh opportunities for emerging companies in a market that is slowly recovering from the pandemic. Several pharmaceuticals firms have
American Airlines (AAL): Here’s what may or may not work for this airline stock
Shares of American Airlines Group (NASDAQ: AAL) have gained 42% since the beginning of this year and 50% over the past 12 months. Despite this, there is a mixed sentiment
